There is no precise, noninvasive manner, pancreatic cancer, the fourth leading cause of cancer deaths in the United States to recognize less. Than 5 % of patients survive five years get full text .
The team’s analysis of four microRNAs in the blood plasma of patients pancreatic cancer pancreatic cancer proof of principle to develop a blood test for this evasive disease Subrata Subrata Sen, associate professor said in MD Anderson Department of Molecular pathology. – Increased expression of microRNAs is known to be involved with specific genetic pathways and processes for the development of cancer-associated changes in cells may be, Sen said. Detect elevated miRNAs in blood plasma of pancreatic cancer patients as informative biomarkers of disease appears to be a promising,. Innovative approach to the development of a minimally invasive test for the detection of this disease. .
‘We urge the the Federal government and the Australian insurance Economics, what other countries have done rethink see and reduce the to use genetic More Information when genetic tests has the potential of morbidity and mortality ‘she says.